WeTrade Group Entered Into A Strategic Partnership With Jiqing, Acquiring Monkeypox Test Kits Exclusive Sales Channel
BEIJING, Aug. 10, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, officially singed the strategic partnership agreement with Jiqing Biomedical Technology Co. Ltd (Jiqing) on 8th August. WeTrade will have the exclusive sales right of monkeypox virus test...
NuraLogix researchers announce AI models that can predict Metabolic Risks
TORONTO, Aug. 10, 2022 /PRNewswire/ -- Researchers at NuraLogix, a global leader in HealthTech AI, announced today that they have developed AI models that can predict a person's risk of Type 2 Diabetes, Hypercholesterolemia, Hypertriglyceridemia and Hypertension. This is important because it will someday allow people to screen themselves using any device with a video camera such as a smartphone...
UC Davis’ new research shows how total-body PET imaging can assess the immunological response to COVID-19 infections
HOUSTON, Aug. 10, 2022 /PRNewswire/ -- UC Davis, a leading university in molecular imaging that collaborated with United Imaging to develop the world's first total-body PET/CT scanner, 'uEXPLORER®,' recently presented their research on COVID-19 at the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. Guided by the uEXPLORER scanner along with a new labeled radiotracer...
Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers
SEATTLE, Aug. 10, 2022 /PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient in Australia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients. Globally, Arbele is the first company exploring the potential of CDH17xCD3 bispecific T-Cell engager antibody in cancer immunotherapy. "Dosing patients is a significant...
Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board
An expert in genitourinary oncology, Dr. Konety brings deep academic insight, broad clinical expertise and a global network to help Asieris advance its innovative pipeline to serve patients worldwide. SHANGHAI, Aug. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (stock code: 688176.SH), a global biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other related...
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine
TAIZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group", Stock code: 02179.HK) is pleased to announce that, the Company has recently completed the subject enrollment and first dose vaccination in respect of immuno-bridging study of its recombinant HPV 9-valent vaccine, REC603, in...
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new DEP® program will generate and evaluate additional DEP® Antibody Drug Conjugates (ADCs). This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC)...
Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board
Co-founder and Board Member Hong-hoi Ting, D.Phil. Appointed Chief Strategy Officer James McCarter, Ph.D. Named Vice President, Head of Radioisotope Technology Research William Diamond, Ph.D., Carl Ross, Ph.D. and Herbert Moore, Ph.D. Join Radioisotope Technology Advisory Board SHANGHAI and BRUSSELS, Aug. 10, 2022 /PRNewswire/ -- Full-Life Technologies Co., Ltd. ("Full-Life") today announced two key appointments to its Radioisotope Technology leadership...
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022
The study confirmed preliminary efficacy and safety of BBT-176 along with its treatment responses in advanced NSCLC patients A patient with the C797S triple mutation showed up to 53 percent reduction in EGFR mutant allelic change VIENNA and SEONGNAM, South Korea, Aug. 10, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company focused on developing...
MedAlliance SELUTION SLR Receives Second FDA IDE Approval
GENEVA, Aug. 10, 2022 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). MedAlliance SELUTION SLR Receives Second FDA IDE Approval This comes only...
